Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine (RIGVIR^®) is currently rising 5.5 Million EUR (0.5 MEUR secured) to finance the commercialization process of next generation solution for unmet medical needs in oncology based on the existing product.

We have elaborated a registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the following:

• Medical need – currently no treatment solutions for both early Melanoma and Uveal Melanoma;
• Target market value exceeds 4.5 Billion EUR annually;
• Company owns a unique and well-established treatment method;
• Company owns a GMP API production and know-how;
• RIGVIR^® has Excellent safety profile;
• New projects are supported by preclinical data and retrospective clinical observations;
• The production and use of ECHO7 virus RIGVIR® have granted strong international IP protection;
• The Company has authorization to start any Phase II clinical trials in the EU.

It is expected that the company value would rise 3 times within the next two years but in 5 to 7 years period – 10 times, at least.

Find Out More